Edition:
United States

Vital Therapies Inc (VTL.OQ)

VTL.OQ on NASDAQ Stock Exchange Global Select Market

5.75USD
11:30am EDT
Change (% chg)

$-0.05 (-0.86%)
Prev Close
$5.80
Open
$5.80
Day's High
$5.82
Day's Low
$5.75
Volume
11,702
Avg. Vol
39,029
52-wk High
$7.20
52-wk Low
$2.25

Chart for

About

Vital Therapies, Inc. is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient's liver to regenerate to a healthy... (more)

Overall

Beta: 4.19
Market Cap(Mil.): $249.02
Shares Outstanding(Mil.): 42.21
Dividend: --
Yield (%): --

Financials

  VTL.OQ Industry Sector
P/E (TTM): -- 185.16 33.25
EPS (TTM): -1.32 -- --
ROI: -95.86 -0.71 13.13
ROE: -96.01 -2.76 14.96

BRIEF-Vital Therapies Announces VTL-308 Reaches Enrollment Target Of 150 Subjects

* VITAL THERAPIES ANNOUNCES VTL-308 REACHES ENROLLMENT TARGET OF 150 SUBJECTS

Mar 22 2018

BRIEF-Vital Therapies Announces Q4 Loss Per Share $0.35

* VITAL THERAPIES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 13 2018

BRIEF-Vital Therapies Appoints Russell J. Cox As Chief Executive Officer And Board Member

* VITAL THERAPIES APPOINTS RUSSELL J. COX AS CHIEF EXECUTIVE OFFICER AND BOARD MEMBER EFFECTIVE JANUARY 3, 2018

Dec 04 2017

BRIEF-Vital Therapies reports Q3 loss per share $0.30

* Vital therapies announces third quarter 2017 financial results

Oct 25 2017

Earnings vs. Estimates